127 related articles for article (PubMed ID: 38065292)
1. Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation.
Kageji H; Momose T; Nagamoto Y; Togashi N; Yasumatsu I; Nishikawa Y; Kihara K; Hiramoto K; Minami M; Kasanuki N; Isoyama T; Naito H
Bioorg Med Chem Lett; 2024 Jan; 98():129575. PubMed ID: 38065292
[TBL] [Abstract][Full Text] [Related]
2. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
3. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
[TBL] [Abstract][Full Text] [Related]
5. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of new pyrimidine derivatives as EGFR
Mao YZ; Xi XX; Zhao HY; Zhang YL; Zhang SQ
Bioorg Med Chem Lett; 2023 Jul; 91():129381. PubMed ID: 37336419
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR
Guo Y; Gao B; Gao P; Wang Y; Gou S
Bioorg Med Chem; 2023 Jul; 90():117338. PubMed ID: 37269687
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
[TBL] [Abstract][Full Text] [Related]
11. Novel anilinopyrimidine derivatives as potential EGFR
Guo Y; Gao B; Gao P; Fang L; Gou S
Bioorg Med Chem; 2022 Sep; 70():116907. PubMed ID: 35810715
[TBL] [Abstract][Full Text] [Related]
12. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Chen H; Lai M; Zhang T; Chen Y; Tong L; Zhu S; Zhou Y; Ren X; Ding J; Xie H; Lu X; Ding K
J Med Chem; 2022 May; 65(9):6840-6858. PubMed ID: 35446588
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
14. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
Dou D; Wang J; Qiao Y; Wumaier G; Sha W; Li W; Mei W; Yang T; Zhang C; He H; Wang C; Chu L; Sun B; Su R; Ma X; Gong M; Xie L; Jiang W; Diao Y; Zhu L; Zhao Z; Chen Z; Xu Y; Li S; Li H
Eur J Med Chem; 2022 Dec; 244():114856. PubMed ID: 36279692
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.
Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M
Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
19. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.
Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y
Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]